A.R.T. Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

A.R.T. Advisors’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,192	Closed	-$13K	–	1959
2017 Q4	$13K	Buy	+10,192	New	+$16.6K	﹤0.01%	1318
2016 Q2	–	Sell	-2,839	Closed	-$15K	–	1883
2016 Q1	$15K	Sell	2,839 -12,000	-81%	-$156K	﹤0.01%	1324
2015 Q4	$255K	Buy	+14,839	New	+$354K	0.01%	1116
2015 Q1	–	Sell	-21,638	Closed	-$1.31M	–	1959
2014 Q4	$1.31M	Buy	+21,638	New	+$1.09M	0.05%	538
2014 Q2	–	Sell	-1,735	Closed	-$112K	–	1787
2014 Q1	$112K	Sell	1,735 -17,236	-91%	-$1.17M	0.01%	1228
2013 Q4	$1.07M	Sell	18,971 -2,241	-11%	-$126K	0.06%	456
2013 Q3	$1.3M	Buy	21,212 +8,956	+73%	+$607K	0.07%	407
2013 Q2	$715K	Buy	+12,256	New	+$754K	0.02%	746

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

A.R.T. Advisors's OREX Position: Q1 2018 in Review

A.R.T. Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2018, closing a stake of 10,192 shares — an estimated $13K sold.

A.R.T. Advisors first reported a position in OREX in Q2 2013 and held it in 8 quarters. The position peaked at $1.31M in Q4 2014. 27 funds tracked by Wall St. Rank hold OREX as of Q1 2018.

A.R.T. Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
A.R.T. Advisors sold 10,192 Orexigen Therapeutics, Inc. shares in Q1 2018, an estimated $13K.
A.R.T. Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 8 quarters.
A.R.T. Advisors's Orexigen Therapeutics, Inc. position peaked at $1.31M in Q4 2014.
27 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2018.

Based on A.R.T. Advisors's 13F filing for Q1 2018, filed 15 May 2018.